NetScientific PLC Dr. Fran s R. Martelet appointed as CEO (7136M)
11 Maio 2015 - 3:01AM
UK Regulatory
TIDMNSCI
RNS Number : 7136M
NetScientific PLC
11 May 2015
NetScientific plc
("NetScientific" or the "Group")
NetScientific appoints Dr. François R. Martelet as Chief
Executive Officer
London, UK - 11 May 2015 - NetScientific (AIM: NSCI), the
biomedical and healthcare technology group, announces the
appointment of Dr François R. Martelet as Chief Executive Officer
and Board Director.
Dr. Martelet will join the Group on 8 June 2015. Sir Richard
Sykes, who has been Executive Chairman prior to this appointment,
will revert to his position as Non-Executive Chairman.
Most recently, Dr. Martelet has served as senior advisor to the
CEO and Interim SVP at Stallergenes SA where he was responsible for
international commercial strategies. During this period, sales
revenues grew by 20+% and various new products were launched,
including Oralair(R), into ex-US markets. Before this, he was CEO
at Topotarget A/S, a publicly traded European biotech company
specialised in oncology therapeutics which he successfully
transformed from a research based organisation into a late-stage
clinical development company ready for a European exit.
Prior to this, Dr Martelet served as CEO of Avax Technologies
Inc., a US biotech company specialised in therapeutic oncology
vaccines. He has also held senior level commercial positions at
Merck & Co, Inc. (VP & Global Franchise Head-Oncology),
Novartis Pharma (SVP & Head of Central & Eastern Europe,
Middle East and Africa), Schering-Plough and Eli Lilly.
Sir Richard Sykes, Chairman of NetScientific, commented: "Dr.
Martelet further strengthens NetScientific's management team at a
time when a number of the Group's portfolio companies will soon be
entering commercialisation. He brings over 20 years of biopharma
experience and a proven track record of shaping and developing
businesses to deliver returns. With his broad experience in both
large and small companies, deep knowledge of commercialisation and
his proven managerial capability, François will be a great asset to
the business in growing its innovative technology portfolio."
Dr Martelet said: "It is a great opportunity to take on the CEO
role at NetScientific, working with the Board and the management
team in the transformation process of its portfolio companies. I am
particularly pleased to work with Sir Richard, whose track record
in the Pharmaceutical and Biotechnology fields is very impressive.
I look forward to being able to shape the direction of
NetScientific's portfolio of game-changing healthcare platform
technologies."
François Regis Martelet, aged 55 years, has been a director of
the following companies during the five years preceding the date of
this announcement:
Current directorships Past Directorships
Pharmaexcellentia SA Avax Technologies Inc.
(personal service company) Ennovance Capital LLC
European BioPharmaceutical Enterprises
There is no further information to be disclosed under Schedule
Two paragraph (g) of the AIM Rules for Companies.
- Ends -
About NetScientific
NetScientific is a biomedical and healthcare technology group
that funds and develops technologies that offer transformative
benefits to people's lives and society through improved diagnosis,
prognosis and treatment. For more information, please visit the
website at www.NetScientific.net
Contact Details
NetScientific Tel: +44 (0)77 2055 5752
Peter Thoms, CFO
Investec Tel: +44 (0)20 7597 4000
Gary Clarence / Daniel Adams
Instinctif Partners Tel: +44 (0)20 7457 2020
Melanie Toyne-Sewell / Jayne Crook Email: netscientific@instinctif.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAGGUUCAUPAPUU
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024